The Priority Review

Tag

primary membranous nephropathy

1 story

  1. Clinical trials

    Amgen registers Phase 3 study of inebilizumab in primary membranous nephropathy

    This study was first posted on ClinicalTrials.gov on October 1, 2026. The study plans to enroll 159 participants and aims to evaluate the efficacy of inebilizumab on PMN disease activity as measured by complete remission.